Editas Medicine is a biotechnology company that focuses on developing transformative therapies based on the groundbreaking gene editing technology known as CRISPR. The company is dedicated to harnessing the power of this technology to correct genetic defects, treat serious diseases, and ultimately improve patient outcomes. Editas is engaged in advancing research and development initiatives aimed at addressing various genetic disorders, including inherited diseases and conditions that currently lack effective treatments, all while driving innovation in the field of genomic medicine. Through collaboration with leading scientists and institutions, Editas aims to bring its pioneering therapies from the lab to the clinic, making a meaningful impact in the lives of patients. Read More
CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it will host a webinar on Tuesday, September 2, 2025, at 8:00 a.m. ET to announce the selection of its lead in vivo development candidate.
CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that management will participate in the following upcoming investor conferences in September:
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Editas Medicine posted Q2 2025 revenue of $3.58M, beating estimates, but EPS loss widened to -$0.63. Stock dipped 1.75% amid restructuring concerns. Pipeline progress includes IND filing plans for 2026.
Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy.
Preclinical studies achieved therapeutically relevant gene editing levels of the HBG1/2 promoter & favorable biodistribution profile in non-human primates using a clinically validated editing strategy
Data demonstrate therapeutically relevant editing levels using a clinically validated strategy, supporting its development as a novel, in vivo approach to treating sickle cell disease and beta thalassemia
Company to share in vivo preclinical data demonstrating the successful use of targeted lipid nanoparticles to deliver HBG1/2 promoter editing cargo to hematopoietic stem and progenitor cells (HSPCs) at ASGCT this week
CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that the U.S. Court of Appeals for the Federal Circuit affirmed-in-part and vacated-in-part the Patent Trial and Appeal Board’s (PTABs) previous decision and remanded it back to the PTAB for further review in the U.S. patent interference involving specific patents for CRISPR/Cas9 editing in human cells between the University of California, the University of Vienna, and Emmanuelle Charpentier and the Broad Institute (Broad). The Company’s in-licensed patents covering CRISPR/Cas12a are not at issue in the interference and are unaffected by this decision.
